Our rapid review process allows you to determine the pricing and access potential of your in/out licensing asset.
Realise the value of an asset
We help you to understand the value of an asset during the in-licensing and out-licensing process
We can evaluate the potential commercial value of an asset through identification of the patient flow and determining the price and reimbursement potential, providing insights on how to improve the asset’s value through the identification of clinical and economic evidence that will resonate with stakeholders
Our ‘Pricing and Market Access Rapid Review’ process is tailored to provide the top-line insights required to feed into your due diligence process
Talk to an expert
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.